文献速递血栓与止血

循环肿瘤DNA预测癌症患者静脉血栓栓塞症

Circulating tumor DNA predicts venous thromboembolism in patients with cancers.
PubMed 文献 · J Thromb Haemost · 2024-09-26

研究纳入美国一家大型安全网医院系统1038例接受ctDNA检测的癌症患者,用Fine-Gray模型分析ctDNA与VTE的关联。调整临床变量后,致病性ctDNA突变数目可预测VTE风险,≥3、2、1个突变相比无突变的 adjusted subdistribution HR 分别为2.75、1.94、1.38(P<.0001)。联合模型时依AUC为0.74(95%CI 0.67-0.80),数值上高于仅临床模型0.71(95%CI 0.64-0.76)。

要点

  • 调整临床变量后,致病性ctDNA存在与VTE独立相关。
  • 致病性突变数目越多,未来VTE风险越高,≥3个突变 adjusted subdistribution HR 2.75。
  • 关联主要由KRAS、PTEN、CDKN2A、NF1和EGFR基因突变驱动。

核心结论

  • ctDNA检测可能作为临床风险评估模型的辅助工具,用于改善癌症患者个体化VTE风险评估与管理。

研究设计与样本

  • 分析美国一家大型安全网医院系统1038例因肿瘤诊疗接受ctDNA检测的癌症患者数据。
  • 采用Fine-Gray模型调整癌症类型、分期、治疗及自初诊起时间后分析ctDNA与VTE关联。
  • 用时依ROC曲线下面积(AUC)评估遗传模型、仅临床模型和联合模型的区分度。

主要发现

  • 调整临床变量后,致病性ctDNA存在与VTE独立相关。
  • 独立于肿瘤类型,致病性ctDNA突变数目可预测未来VTE风险:≥3、2、1个突变相比无突变的 adjusted subdistribution HR 分别为2.75、1.94、1.38(P<.0001)。
  • 关联主要由KRAS、PTEN、CDKN2A、NF1和EGFR基因突变驱动。
  • 联合临床与ctDNA模型时依AUC为0.74(95%CI 0.67-0.80),仅临床模型为0.71(95%CI 0.64-0.76),联合模型数值上更高。

关键数值与推荐

  • 致病性ctDNA突变≥3个相比无突变 adjusted subdistribution HR 2.75(P<.0001)。
  • 致病性ctDNA突变2个相比无突变 adjusted subdistribution HR 1.94(P<.0001)。
  • 致病性ctDNA突变1个相比无突变 adjusted subdistribution HR 1.38(P<.0001)。
  • 联合模型时依AUC 0.74(95%CI 0.67-0.80)vs 仅临床模型0.71(95%CI 0.64-0.76)。

临床怎么用

  • 原文结论认为ctDNA检测可能作为临床风险评估模型的辅助工具,用于改善癌症患者个体化VTE风险评估与管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite rapid advances in liquid biopsy for circulating tumor DNA (ctDNA), its prognostic value for venous thromboembolism (VTE) in patients with cancer is underexplored, particularly in underserved and minoritized populations. OBJECTIVES: To evaluate the role of ctDNA in risk stratification for cancer-associated VTE. METHODS: We analyzed data from 1038 cancer patients who underwent ctDNA measurement for oncologic care at a large safety-net hospital system in the United States. We investigated the association between ctDNA and VTE after adjusting for cancer type, stage, treatment, and time from initial diagnosis using Fine-Gray models. We further assessed the discrimination of the genetic, clinical-only, and combined models using the area under the time-dependent receiver operating characteristic curve (AUC). RESULTS: The presence of pathogenic ctDNA was independently associated with VTE after adjusting for clinical variables. Independent of tumor type, the number of pathogenic ctDNA mutations was predictive of future VTE risk (adjusted subdistribution hazard ratios of 2.75, 1.94, and 1.38 for ≥3, 2, and 1 pathogenic mutation, respectively, compared with none; P < .0001). The association was primarily driven by mutations in KRAS, PTEN, CDKN2A, NF1, and EGFR genes. Compared with the clinical-only model (AUC, 0.71; 95% CI, 0.64-0.76), the combined clinical and ctDNA model had a numerically higher time-dependent AUC (AUC, 0.74; 95% CI, 0.67-0.80). CONCLUSION: ctDNA testing may serve as an adjunctive tool to clinical risk assessment models in cancer patients to improve personalized VTE risk assessment and management.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Ma S, Jiang JY, Kim RB, et al. Circulating tumor DNA predicts venous thromboembolism in patients with cancers. J Thromb Haemost. 2024. PMID: 39341370. doi:10.1016/j.jtha.2024.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。